載入中
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
最新資料
¥622
+¥10.00 · +1.63%
盤中時間採用JST。市場資料可能有所延遲。
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
日內區間
目前¥622
52週區間
目前¥622
盤中時間採用JST。市場資料可能有所延遲。
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
日內區間
目前¥622
52週區間
目前¥622
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（JPY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.31億 JPY | 5444.6萬 JPY | 6111.2萬 JPY | 3.74億 JPY | 7.08億 JPY |
| 銷貨成本 | 1.53億 JPY | 5288.4萬 JPY | 6149萬 JPY | 1.51億 JPY | 1.4億 JPY |
| 毛利 | 7840萬 JPY | 156.2萬 JPY | −37.8萬 JPY | 2.24億 JPY | 5.68億 JPY |
| 研究與開發 | — | 4.7億 JPY | 3.76億 JPY | 3.04億 JPY | 2.66億 JPY |
| 銷售、一般及管理費用 | 9.07億 JPY | 4.28億 JPY | 3.21億 JPY | 3.45億 JPY | 2.31億 JPY |
| 營業費用 | 9.07億 JPY | 8.98億 JPY | 6.97億 JPY | 6.49億 JPY | 4.98億 JPY |
| 利息收入 | 380.7萬 JPY | 48萬 JPY | 4萬 JPY | 4.1萬 JPY | 17.6萬 JPY |
| 利息支出 | 1427.9萬 JPY | 951.4萬 JPY | 977.4萬 JPY | 745.7萬 JPY | 523.6萬 JPY |
| 折舊和攤銷 | 3549.4萬 JPY | 3601.7萬 JPY | 3812.2萬 JPY | 5428.5萬 JPY | 1849.6萬 JPY |
| 營業利益 | −8.28億 JPY | −8.96億 JPY | −6.97億 JPY | −4.25億 JPY | 7057萬 JPY |
| 淨利 | −7.64億 JPY | −8.72億 JPY | −5.89億 JPY | −4.74億 JPY | 1.43億 JPY |
公司資料更新於 2026年10月10日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
